This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, M.
Right arrow Articles by Palefsky, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, M.
Right arrow Articles by Palefsky, J. M.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, Mar 1996, 205-210, Vol 3, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia

M Nakagawa, DP Stites, S Farhat, A Judd, AB Moscicki, AJ Canchola, JF Hilton and JM Palefsky
Department of Laboratory Medicine, School of Medicine, University of California at San Francisco 94143-0134, USA.

The incidence of human papillomavirus (HPV)-related cervical intraepithelial neoplasia (CIN) and cervical cancer is increased with immunodeficiency, but the role of immune response, including cell- mediated immunity, in disease prevention is not well understood. In this study, T-cell proliferative responses to six synthetic peptides with predicted immunogenic determinants from the HPV-16 E4, E6, E7, and L1 open reading frames were analyzed in 22 sexually active women with new-onset CIN and 65 sexually active women without cervical disease, characterized by cytology, colposcopy, and HPV testing. T-cell proliferative responses were demonstrated to all six HPV-16 peptides. Although not statistically significant, rates of reactivity to E6 (24- 45) were higher among sexually active women without disease (26%) than among women with current CIN (7%), as was the overall number of peptides stimulating a response. Women with CIN may not respond to selected HPV antigens as well as women without disease do.


This article has been cited by other articles:

  • Villada, I. B., Barracco, M. M., Ziol, M., Chaboissier, A., Barget, N., Berville, S., Paniel, B., Jullian, E., Clerici, T., Maillere, B., Guillet, J. G. (2004). Spontaneous Regression of Grade 3 Vulvar Intraepithelial Neoplasia Associated with Human Papillomavirus-16-Specific CD4+ and CD8+ T-Cell Responses. Cancer Res. 64: 8761-8766 [Abstract] [Full Text]  
  • de Jong, A., van Poelgeest, M. I. E., van der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J. M., Kenter, G., Offringa, R., van der Burg, S. H. (2004). Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6. Cancer Res. 64: 5449-5455 [Abstract] [Full Text]  
  • Luxton, J. C., Nath, R., Derias, N., Herbert, A., Shepherd, P. S. (2003). Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J. Gen. Virol. 84: 1063-1070 [Abstract] [Full Text]  
  • Nakagawa, M., Viscidi, R., Deshmukh, I., Costa, M. D., Palefsky, J. M., Farhat, S., Moscicki, A.-B. (2002). Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women. CVI 9: 877-882 [Abstract] [Full Text]  
  • Theodore, C., Androulakis, N., Spatz, A., Goujard, C., Blanchet, P., Wibault, P. (2002). An explosive course of squamous cell penile cancer in an AIDS patient. Ann Oncol 13: 475-479 [Abstract] [Full Text]  
  • Moscicki, A.-B., Hills, N., Shiboski, S., Powell, K., Jay, N., Hanson, E., Miller, S., Clayton, L., Farhat, S., Broering, J., Darragh, T., Palefsky, J. (2001). Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young Females. JAMA 285: 2995-3002 [Abstract] [Full Text]  
  • Scott, M., Nakagawa, M., Moscicki, A.-B. (2001). Cell-Mediated Immune Response to Human Papillomavirus Infection. CVI 8: 209-220 [Full Text]  
  • Muderspach, L., Wilczynski, S., Roman, L., Bade, L., Felix, J., Small, L. A., Kast, W. M., Fascio, G., Marty, V., Weber, J. (2000). A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia Who Are HPV 16 Positive. Clin. Cancer Res. 6: 3406-3416 [Abstract] [Full Text]  
  • Palefsky, J. M. (1998). Human Papillomavirus Infection and Anogenital Neoplasia in Human Immunodeficiency Virus-Positive Men and Women. J Natl Cancer Inst Monogr 1998: 15-20 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»